Breaks Categories: Stock Spotlights

FridayMar 03, 2017 11:15 am

NetworkNewsBreaks – aTyr Pharma, Inc. (NASDAQ: LIFE) Receives EMA Orphan Drug Designation for Resolaris™; Shares Pull from Early Gains

Reversing from a pre-market spike, shares of aTyr Pharma (NASDAQ: LIFE) are down 4% on word that the company’s Resolaris™ has received Orphan Drug Designation from the European Medicines Agency (EMA) for the treatment of limb girdle muscular dystrophy (LGMD) patients. Orphan designation was advised following a positive opinion by the EMA's Committee for Orphan Medicinal Products. Medicines that receive the designation are eligible for various incentives, including assistance with development of the medicine; reduced fees for marketing-authorization applications; and extended market exclusivity once the medicine is authorized. The company also received Orphan Drug Designation from the U.S. FDA earlier…

Continue Reading

ThursdayMar 02, 2017 1:22 pm

NetworkNewsBreaks – ORHub, Inc. (ORHB) Collaborates with Microsoft (NASDAQ: MSFT) on Solution to Alleviate Costly Aspect of Health Care

ORHub (OTC: ORHB) today introduced a new solution, built on Microsoft’s (NASDAQ: MSFT) Azure enterprise-grade cloud computing platform, that focuses on the single biggest cost center for health care: surgery. The company has created a value-based solution that tracks the cost of treating a condition from diagnosis to discharge, as well as outcomes that resulted from that treatment. This results in decreases in cost and improvement in outcomes by eliminating inefficiencies, duplication of effort, and errors and omissions. The company worked with Microsoft for Startups on a variety of technical engagements that helped create the digital platform's initial architecture. The…

Continue Reading

ThursdayMar 02, 2017 11:47 am

NetworkNewsBreaks – Innovus Pharma (INNV) Receives Receipt of Notification to Commercialize Zestra® in the EU; Shares Rise

Innovus Pharmaceuticals (OTCQB: INNV) shares are higher this morning after the company said that it received the CPNP notification number required to commercialize Zestra® in all 28 member countries of the European Union. The over-the-counter consumer goods and specialty pharmaceutical company is engaged in commercialization, licensing and development of safe and effective non-prescription medicine. In addition to the largest market for Zestra®, the United States, Innovus Pharma currently generates Zestra® revenues from markets in Canada, Morocco, certain European countries and Hong Kong. “We are pleased to expand the commercialization market for Zestra® to the second largest market in the world…

Continue Reading

ThursdayMar 02, 2017 11:40 am

NetworkNewsBreaks – CFN Media Examines Singlepoint’s (SING) “Low-Risk Approach to the Cannabis Industry” in New Article

Earlier today, Singlepoint, Inc. (OTC: SING) was revealed as the focus of an article (http://nnw.fm/VKmu4) published by CFN Media Group, a creative agency and digital media network dedicated to the legal cannabis industry. More specifically, the CFN article focuses on recent comments by White House Press Secretary Sean Spicer regarding the enforcement of federal cannabis regulations, as well as what those regulations could mean for Singlepoint’s operations in the cannabis space. “Singlepoint has stepped in to address some of these industry challenges with its own solutions in a way that doesn't involve touching the drug at all,” the article notes.…

Continue Reading

ThursdayMar 02, 2017 9:47 am

NetworkNewsBreaks – National Waste Management Holdings, Inc. (NWMH) Acquires Burts Refuse LLC in Upstate New York

Emerging vertically integrated solid waste management company National Waste Management Holdings, Inc. (OTC: NWMH) this morning announced the acquisition of Burts Refuse LLC, in line with its previously outlined commitment to completing one acquisition per quarter. Located in West Davenport, New York, Burst Refuse is a waste disposal and recycling business whose acquisition is expected to bolster National Waste’s growing footprint in Upstate New York. Additionally, the transaction will add trucks, equipment and containers to National Waste’s existing line of equipment, strengthening the company’s ability to attract new customers and business relationships. “We are pleased to demonstrate to shareholders our…

Continue Reading

WednesdayMar 01, 2017 12:49 pm

NetworkNewsBreaks – SRAX (NASDAQ: SRAX) Presenting at 29th Annual ROTH Conference; CEO, CFO to Host Investor Meetings

SRAX (NASDAQ: SRAX), an Internet advertising and platform technology company that provides tools to automate the digital advertising market, is set to present at the 29th Annual ROTH Conference. The company’s presentation will take place on Monday, March 13, 2017, at 5:30 p.m. PT in Dana Point, CA. Additionally, the company’s chief executive officer, Chris Miglino, and chief financial officer, J.P. Hannan, will be hosting one-on-one meetings with investors throughout the day. If you are interested in scheduling a one-on-one meeting, please contact your ROTH representative. To view the full press release, visit: http://nnw.fm/2L0nt About SRAX SRAX is an Internet…

Continue Reading

TuesdayFeb 28, 2017 12:22 pm

NetworkNewsBreaks – NF Energy Saving Corp. (NASDAQ: NFEC) Shares Tick Higher on New Sales Contract

NF Energy (NASDAQ: NFEC) shares are up more than 10% after the energy saving service solutions provider for China's power said it recently signed a $340,000 sales contract with Sinkiang Production and Construction Group to supply a project with butterfly valves. This is the first contract signed in 2017 based upon China's "one belt and one road" developmental strategy for the future. NF Energy intends to use this strategy to expand its market by growing is brand in its local region and nearby countries. Per the agreement, the company is expected to deliver this equipment in the third quarter of…

Continue Reading

TuesdayFeb 28, 2017 9:41 am

NetworkNewsBreaks – aTyr Pharma, Inc.’s (NASDAQ: LIFE) Resolaris™ Granted Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy; Shares Higher

Shares of aTyr Pharma (NASDAQ: LIFE) are up more than 15% after the company said its lead product candidate, Resolaris™, received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of limb girdle muscular dystrophy (LGMD) patients. Resolaris is derived from a naturally occurring protein released by human skeletal muscle cells and is being developed as an intravenous protein therapeutic for the treatment of rare myopathies with an immune component, such as LGMD. Being granted Orphan Drug Designation by the FDA will advance the development of Resolaris and create opportunity for incentives under the program.…

Continue Reading

MondayFeb 27, 2017 12:01 pm

NetworkNewsBreaks – OncoSec’s (NASDAQ: ONCS) ImmunoPulse® IL-12 Receives Fast Track Designation to Treat Metastatic Melanoma

OncoSec Medical (NASDAQ: ONCS) has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its ImmunoPulse® IL-12, a potentially first-in-class, Intratumoral anti-cancer gene therapy that expresses interleukin-12 (IL-12) for the treatment of metastatic melanoma, following progression on pembrolizumab or nivolumab. The company this morning announced that this designation permits frequent communications and meetings with the FDA, providing opportunity for the upcoming phase 2b PISCES clinical trial of ImmunoPulse® IL-12 in combination with an intravenous anti-PD-1 antibody. The clinical trial is planned to initiate in the first half of 2017. "With the recent presentation of our interim…

Continue Reading

FridayFeb 24, 2017 11:10 am

NetworkNewsBreaks – Auris Medical’s (NASDAQ: EARS) AM-111 Receives FDA Fast Track Designation to Treat Acute Sensorineural Hearing Loss

Auris Medical (NASDAQ: EARS) shares rose 13% this morning on news of the reception of Fast Track designation for AM-111 in the treatment of acute sensorineural hearing loss (ASNHL) from the U.S. Food and Drug Administration (FDA). The company is currently evaluating AM-111 in two phase 3 clinical trials. The first is the HEALOS trial, which is being conducted in several European and Asian countries. Auris Medical expects to complete enrollment in the second quarter of 2017 and report top-line results from this trial in the third quarter of 2017. The second trial, ASSENT, is being conducted in the U.S.,…

Continue Reading